Role of Uromodulin in Management of Multiple Myloma

Launched by ASSIUT UNIVERSITY · Mar 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a substance called uromodulin to see how it can help in diagnosing and managing a condition called multiple myeloma, which is a type of blood cancer. Researchers want to find out if measuring uromodulin levels can help identify kidney problems early on in patients with multiple myeloma and if it can provide important information about how well patients might respond to treatments.

To be eligible for this trial, participants need to be adults aged 18 and older who have recently been diagnosed with multiple myeloma, whether or not they have kidney issues. However, individuals whose kidney problems are caused by conditions other than multiple myeloma, such as diabetes or high blood pressure, will not be included. While the trial is not yet open for recruitment, those who participate can expect to undergo tests to measure their uromodulin levels and will be closely monitored throughout the study. This research could be important for improving how multiple myeloma is diagnosed and treated in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients ≥ 18 years old that newly diagnosed with multiple myeloma according to 2024 updates in diagnosis of multiple myeloma (10) with and without renal impairment at nephrology and haematology unit of internal medicine department.
• Exclusion Criteria:
• • any patient have evidence of renal impairment due to any cause other than multiple myeloma as diabetic nephropathy, hypertensive nephropathy or lupus nephritis ... etc.